Kobilka Institute of Innovative Drug Discovery (KIIDD) and Arieh Warshel Institute of Computational Biology (AWI) were established on April 10, 2017 and are the first batch of Nobel laureate labs at the University. Led by Prof. Brian K. Kobilka, the Nobel laureate in Chemistry in 2012, the Kobilka Institute of Innovative Drug Discovery (KIIDD) is a significant milestone in the University’s attempt to evolve into a world research university.
Professor Brian K. Kobilka earned his M.D., cum laude, from Yale University School of Medicine. He was named a member of the National Academy of Sciences in 2011. He received the Nobel Prize in Chemistry with Robert Lefkowitz for discovering the inner workings of G protein-coupled receptors in 2012. His work has significantly influenced pharmaceutical research and manufacturing. He is a professor at Stanford University Department of Molecular and Cellular Physiology. He has become a distinguished professor of The Chinese University of Hong Kong, Shenzhen since February 2017.
KIIDD will focus on new drug development which includes drugs receptor structural biology research, computational chemistry research, the function of the drug molecules in organic synthesis and medicinal chemistry research, receptor function the function of the drug molecule pharmacology, etc. Researchers in KIIDD are going to carry out studies about the structural biology of drug receptors through lots of modern biological techniques, such as single crystal x-ray diffraction, Nuclear magnetic resonance (NMR) and electron microscopy. CAD and molecular simulations were used in the drug designs. KIIDD lay eyes on functional drug synthesis, medicinal chemistry and pharmacology, to further explore the pathways to make new drugs, as well as offering intellectual support on pharmacology for future clinical research.
Aims and perspectives of KIIDD are: 1. Introducing the world's top talent team in the strategic field of new medicine, obtaining innovations and breakthroughs in production, learning, research, and helping bring the world's top technology and improve the industry development in related fields in Shenzhen; 2. Carrying out basic scientific research and make sure of industrialization of biomedical technology, Shenzhen develop into a globally important and world-leading biopharmaceutical industry base and cultivate a batch of pharmaceutical companies with international competitiveness; 3. To become an open and high-tech enterprise with high potential for settlement and high-end technology service platform; 4. To vigorously promote the Chinese University of Hong Kong (Shenzhen) and other higher education institutions in Shenzhen to cultivate a new generation of innovative pharmaceutical research and industrialization professionals for China and Shenzhen.